Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
주식 순위 #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
주가
$4.74
마지막 동기화: 2026-08-31
시가총액
$372.19M
변동 (1일)
-2.47%
변동 (1년)
-1.04%
국가
US
거래 Lexeo Therapeutics, Inc. Common Stock (LXEO)

카테고리

Lexeo Therapeutics, Inc. Common Stock (LXEO)의 주식 분할 이력
Lexeo Therapeutics, Inc. Common Stock 주식 (심볼: LXEO)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Sep 01, 2026에 발생했습니다.
Sep 01, 2026 이전에 매수한 LXEO 주식 1주는 현재 0주의 LXEO 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH